BIO Quote, Financials, Valuation and Earnings

Bionano Genomics, Inc. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -115.42%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Bionano Genomics, Inc.'s return on equity of -84.77%.

Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 8.73%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 341.18%. Given that Bionano Genomics, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc. has a beta of 1.185, which suggesting that the stock is 18.506% more volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 2.336, suggesting its more volatile than the S&P 500 by 133.592%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.

Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.44x versus 0.20x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -6.8%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Bruker Corp.'s return on equity of -1.2%.

Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 8.73%. On the other hand Bruker Corp. has an analysts' consensus of $48.83 which suggests that it could grow by 0.94%. Given that Bio-Rad Laboratories, Inc. has higher upside potential than Bruker Corp., analysts believe Bio-Rad Laboratories, Inc. is more attractive than Bruker Corp..

Bio-Rad Laboratories, Inc. has a beta of 1.185, which suggesting that the stock is 18.506% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.405%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.41% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Bruker Corp.'s net income of -$58.5M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.44x versus 2.14x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -5.98%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 8.73%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 176.66%. Given that Harvard Bioscience, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc. has a beta of 1.185, which suggesting that the stock is 18.506% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.123%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.

Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.44x versus 0.37x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of 7.29%. Bio-Rad Laboratories, Inc.'s return on equity of -9.77% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Bio-Rad Laboratories, Inc. has a consensus price target of $348.00, signalling upside risk potential of 8.73%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that Bio-Rad Laboratories, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Bio-Rad Laboratories, Inc. is more attractive than Phibro Animal Health Corp..

Bio-Rad Laboratories, Inc. has a beta of 1.185, which suggesting that the stock is 18.506% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Rad Laboratories, Inc. quarterly revenues are $653M, which are larger than Phibro Animal Health Corp. quarterly revenues of $363.9M. Bio-Rad Laboratories, Inc.'s net income of -$341.9M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 27.23x while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 3.44x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.